Medtronic financials
$87.09−2.69%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q1 '27 Jul 31 | Q4 '26 Apr 24 | Q3 '26 Jan 23 | Q2 '26 Oct 24 | Q1 '26 Jul 25 | Q4 '25 Apr 25 | Q3 '25 Jan 24 | Q2 '25 Oct 25 | Q1 '25 Jul 26 | Q4 '24 Apr 26 | Q3 '24 Jan 26 | Q2 '24 Oct 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.76B | $9.81B | $9.02B | $8.96B | $8.58B | $8.93B | $8.29B | $8.40B | $7.92B | $8.59B | $8.09B | $7.98B |
| Gross profit | $6.34B | $6.41B | $5.76B | $5.90B | $5.58B | $5.78B | $5.51B | $5.46B | $5.15B | $5.54B | $5.31B | $5.22B |
| Gross margin | 65.0% | 65.4% | 63.8% | 65.8% | 65.0% | 64.7% | 66.5% | 64.9% | 65.1% | 64.6% | 65.6% | 65.4% |
| Operating income | $1.76B | $1.75B | $1.50B | $1.71B | $1.44B | $1.47B | $1.64B | $1.56B | $1.28B | $1.05B | $1.48B | $1.34B |
| Net income | $1.47B | $1.24B | $1.14B | $1.37B | $1.04B | $1.06B | $1.29B | $1.27B | $1.04B | $654.0M | $1.32B | $909.0M |
| Net margin | 15.1% | 12.7% | 12.7% | 15.3% | 12.1% | 11.8% | 15.6% | 15.1% | 13.2% | 7.6% | 16.3% | 11.4% |
| Diluted EPS | $1.14 | $0.97 | $0.89 | $1.07 | $0.81 | $0.82 | $1.01 | $0.99 | $0.80 | $0.49 | $0.99 | $0.68 |
| EBITDA | $2.56B | $2.69B | $2.32B | $2.46B | $2.26B | $2.78B | $2.37B | $2.27B | $2.07B | $1.06B | $2.15B | $2.12B |
| Operating cash flow | $1.79B | $2.57B | $2.74B | $925.0M | $1.09B | $2.53B | $2.57B | $958.0M | $986.0M | $2.78B | $2.47B | $661.0M |
| Free cash flow | $1.29B | $2.08B | $2.30B | $457.0M | $584.0M | $2.07B | $2.10B | $554.0M | $466.0M | $2.35B | $2.13B | $200.0M |
| Diluted shares | 1,285.1M | 1,287.8M | 1,289.5M | 1,288.0M | 1,287.1M | 1,290.0M | 1,286.2M | 1,286.9M | 1,296.5M | 1,323.4M | 1,331.7M | 1,331.9M |
Balance sheet
| Period end | Jul 31 | Apr 24 | Jan 23 | Oct 24 | Jul 25 | Apr 25 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.69B | $1.95B | $1.15B | $1.28B | $1.27B | $2.22B |
| Short-term investments | $7.13B | $7.27B | $7.24B | $7.04B | $6.85B | $6.75B |
| Total debt | $28.15B | $27.96B | $28.07B | $29.10B | $28.61B | $28.52B |
| Total assets | $93.31B | $93.03B | $91.48B | $91.35B | $90.97B | $91.68B |
| Total liabilities | $42.45B | $42.96B | $42.29B | $42.49B | $42.84B | $43.42B |
| Shareholders' equity | $50.85B | $50.07B | $49.20B | $48.86B | $48.13B | $48.26B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology